Hydroxyurea has been used since the early 1970s to potentiate the effects of radiation in the treatment of primary gliomas
METHODS: A total of 64 patients with
Combining imatinib with hydroxyurea is effective in some patients with malignant glioma
Introduction Hydroxyurea (HU) is a well-known genotoxic agent whose biological impact on living organisms has been known for almost a century [ 1 ]
This is an open-label, single stage, uncontrolled, non-randomized Phase II study of continuous, daily doses of imatinib mesylate & hydroxyurea in adult patients
Combining imatinib with hydroxyurea is effective in some patients with malignant glioma
Purpose: This study was designed to evaluate a combined modality treatment for malignant gliomas using radiation therapy with a radiosensitizer and an adjuvant chemotherapy regimen designed to modify resistance to BNCU
This topic review discusses hydroxyurea
SummaryKaryotypic studies of human gliomas are often limited by a low mitotic index and the appearance of contracted chromosomes that do not exhibit clear banding patterns
Methods: We employ a “3+3” dose escalation design to determine the
Since then it has become a well-established drug used to treat a variety of diseases, such as in combination
Common side effects include bone marrow suppression, lack of appetite, vomiting, diarrhea, mouth and stomach ulcers, loss of toenails and/or hair coat
It is taken by mouth
BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma
For sickle cell anemia: For oral dosage form (capsules): Adults—Dose is based on body weight and must be determined by your doctor
Background: Based on the encouraging activity and low toxicity of imatinib mesylate and hydroxyurea among adults with recurrent malignant glioma, we evaluated this combination among patients with recurrent/progressive low-grade gliomas (LGG)
joint stiffness or swelling
(IV) of malignant gliomas, is relatively rare, occurring at a rate of seven per 100 000 tumors, yet is common among brain tumors
In the only randomized study, a statistically significant increase in time to tumor progression for glioblastoma patients was noted for those receiving hydroxyurea
Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928